Sangamo Therapeutics (SGMO)
(Delayed Data from NSDQ)
$0.50 USD
-0.06 (-10.15%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $0.50 0.00 (-0.02%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum F VGM
Brokerage Reports
Sangamo Therapeutics, Inc. [SGMO]
Reports for Purchase
Showing records 21 - 40 ( 322 total )
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Streamlining Focus on ST-920, TX200 Neuro Epigenetic Programs; Prelim 1Q23
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q22 Results; Fabry Program Shines; CAR-Treg Program Advances; Sickle Cell Program in Flux; Modulating PT to $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Upgrading to OUTPERFORM; Ph1/2 STAAR Data Shines at WORLDSymposium; Q4/FY22
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2023 Outlook - New Commercial Launches, Clinical Catalysts & M&A Driving Value
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Latest Data Cuts From Hem-A and Sickle Cell Programs at ASH Demonstrate Progress on Key Programs; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ASH 2022: Ph1/2 Updates for SB-525/HemA and SAR445136/ SCD Programs
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q22 Results; Wholly-Owned Fabry, CAR Treg, and Sickle Cell Programs Each on Track With Potential Near-Term Catalysts
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q3: Ph1/2 Updates for SAR445136/SCD and SB-525/HemA at ASH; Pipeline Progress
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Additional Ph1/2 STAAR Update for ST-920/Fabry at ESGCT
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
STAAR Continues to Shine With Latest Fabry Disease Update at ESGCT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Recruitment Reopened for AFFINE Trial of SB-525/HemA; Dosing Expected in Oct
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Encouraging Ph1/2 Update at SSIEM for ST-920/Fabry; Additional Data in H2:22
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q22 Results; Best-in-Class Fabry Program Continues to Shine With Next Update Expected Later This Month; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P